{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:42:56Z","timestamp":1786545776531,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1038\/s41395-018-0183-8","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T07:14:03Z","timestamp":1530083643000},"page":"1417-1419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Management of GERD: Are Potassium-Competitive Acid Blockers Superior to Proton Pump Inhibitors?"],"prefix":"10.14309","volume":"113","author":[{"given":"Yoshikazu","family":"Kinoshita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihisa","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210302","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ajg.2012.19","article-title":"Efficacy of twicedaily rabeprazole for reflux esophagitis patients refractory to standard once-daily administration of PPI: the Japan-based TWICE study.","volume":"107","author":"Kinoshita","year":"2012","journal-title":"Am J Gastroenterol"},{"key":"R2-5-20210302","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1007\/s00535-008-2214-5","article-title":"Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease.","volume":"43","author":"Uemura","year":"2008","journal-title":"J Gastroenterol"},{"key":"R3-5-20210302","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1124\/jpet.110.170274","article-title":"1-5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.","volume":"335","author":"Hori","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"R4-5-20210302","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.bcp.2011.02.009","article-title":"A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands.","volume":"81","author":"Matsukawa","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"R5-5-20210302","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1124\/jpet.111.179556","article-title":"A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.","volume":"337","author":"Hori","year":"2011","journal-title":"J Pharmacol Exp Ther"},{"key":"R6-5-20210302","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/apt.13121","article-title":"Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.","volume":"41","author":"Jenkins","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-5-20210302","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/apt.13325","article-title":"Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects-a randomised open-label cross-over study.","volume":"42","author":"Sakurai","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R8-5-20210302","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/apt.13588","article-title":"Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.","volume":"43","author":"Kagami","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-5-20210302","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/apt.13331","article-title":"Randomised clinical trial: a doseranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.","volume":"42","author":"Ashida","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"R10-5-20210302","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/apt.13461","article-title":"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.","volume":"43","author":"Ashida","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"R11-5-20210302","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1177\/1756283X17705329","article-title":"A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis.","volume":"10","author":"Iwakiri","year":"2017","journal-title":"Ther Adv Gastroenterol"},{"key":"R12-5-20210302","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000456072","article-title":"Efficacy of vonoprazan for proton pump inhibitor-resistant reflux esophagitis.","volume":"95","author":"Hoshino","year":"2017","journal-title":"Digestion"},{"key":"R13-5-20210302","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.kjms.2017.07.004","article-title":"Vonoprazan treatment improves gastrointestinal symptoms in patients with gastroesophageal reflux disease.","volume":"33","author":"Shinozaki","year":"2017","journal-title":"Kaohsiung J Med Sci"},{"key":"R14-5-20210302","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3892\/br.2016.828","article-title":"Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia.","volume":"6","author":"Asaoka","year":"2017","journal-title":"Biomed Rep"},{"key":"R15-5-20210302","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.curtheres.2016.12.001","article-title":"Evaluation of the efficacy and safety of vonoprazan in patients with nonerosive gastroesophageal reflux disease: a phase III, randomized, double-blind, placebo-controlled, multi-center study.","volume":"81-","author":"Kinoshita","year":"2016","journal-title":"Curr Ther Res Clin Exp"},{"key":"R16-5-20210302","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00535-008-2186-5","article-title":"A randomized, double-blind, placebo-controlled clinical study of the histamine H2-receptor antagonist famotidine in Japanese patients with nonerosive reflux disease.","volume":"43","author":"Hongo","year":"2008","journal-title":"J Gastroenterol"},{"key":"R17-5-20210302","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1046\/j.1365-2036.1999.00558.x","article-title":"Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis.","volume":"13","author":"JE Richter, Kovacs","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"key":"R18-5-20210302","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2036.2010.04508.x","article-title":"Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux disease.","volume":"33","author":"Kinoshita","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"R19-5-20210302","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association.","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterology"},{"key":"R20-5-20210302","doi-asserted-by":"crossref","first-page":"182","DOI":"10.5056\/jnm18001","article-title":"Advantages and disadvantages of long-term proton pump inhibitor use.","volume":"24","author":"Kinoshita","year":"2018","journal-title":"J Neurogastroenterol Motil"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0183-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/00000434-201810000-00005","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/s41395-018-0183-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:46:24Z","timestamp":1786542384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201810000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1038\/s41395-018-0183-8","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}